Imvotamab (IGM-2323), a CD20xCD3 bispecific IGM antibody featuring a dual-action mechanism, promotes physiological T cell activation to avoid both over-stimulation and immune function down-regulation. This compound is under development for addressing B-cell malignant tumors, including multiple myeloma (MM) and non-Hodgkins lymphoma (NHL) [1] [2] [3] [4].
CAS Nummer:
[2573121-53-4]
Target-Kategorie:
Immunology/Inflammation related
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
